Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2023 | Factors to consider when manufacturing CAR T-cells for patients with R/R multiple myeloma

Maximilian Merz • 10 Dec 2023
ASH 2023
Multiple Myeloma Antibodies CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Maximilian Merz, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, explores predictors for successful CAR-T cell production for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (MM). He mentions that chemotherapy within 6 months prior to apheresis is linked to poorer production, whereas bridging therapy with bispecific antibodies does not impact CAR-T manufacture, provided a washout period of 4-8 weeks. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria: Amgen, Takeda, BMS, Janssen, Stemline, Roche

More from Maximilian Merz

CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM 1:34
CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM
Maximilian Merz • 10 Dec 2023
Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM 1:52
Single-cell and immune sequencing to predict response and resistance to CAR-T therapy in R/R MM
Maximilian Merz • 10 Dec 2023
Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort 2:08
Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort
Maximilian Merz • 24 Mar 2022
Approval of cilta-cel by the FDA and its impact on the treatment landscape 1:52
Approval of cilta-cel by the FDA and its impact on the treatment landscape
Maximilian Merz • 24 Mar 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals